# A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Moderate to Severe Active Crohn's Disease

> **NCT00207662** · PHASE3 · COMPLETED · sponsor: **Centocor, Inc.** · enrollment: 580 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** infliximab or placebo

## Key facts

- **NCT ID:** NCT00207662
- **Lead sponsor:** Centocor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-07
- **Primary completion:** —
- **Final completion:** 2005-11
- **Target enrollment:** 580 (ACTUAL)
- **Last updated:** 2010-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00207662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00207662, "A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Moderate to Severe Active Crohn's Disease". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00207662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*